·Î¶¯ÂöÖØ½¨,pulmonary artery reconstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ͳ¼Æ²ÎÊýµØÍ¼,Statistical parametric mappingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍÑÑõ°ûÜÕ/ÖÎÁÆÓ¦ÓÃ,deoxycytidine/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ°°×ÀÒ°±ËἤøÒÖÖÆ¼Á,Protein tyrosine kinase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ÁÁ¿Ç¿¶È,Dose intensityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃâÒßÒÖÖÆÒò×Ó,Immunosuppressive factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿ÉÈÜÐÔ°×ϸ°û½éËØ-6ÊÜÌå,Soluble Interleukin-6 ReceptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍíÆÚ·ÎÏÙ°©,Advanced lung adenocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
4.1µ°°×,Protein 4.1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌøÔ¾×ªÒÆ,Skip metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î¸ôÀë¹à×¢,isolated lung perfusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µòÍöÒÖÖÆÒò×Ó,apoptosis inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶à·Ö±æÂÊÖ±·½Í¼,multi-resolution histogramÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
G1ÆÚ×èÖÍ,G 1 arrestÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö¸Éϸ°û²â¶¨,Tumor stem cell assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éÖ¯·Ö»¯,Tissue differentiationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Áܰ͹ÜÇÖ·¸,Lymphatic vessel invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ê´óÐԹǹؽڲ¡,hypertrophic osteoarthropathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È¥¼×°ßòúËáÄÆ,Sodium DemethylcantharidateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô¤·ÀÐÔÄÔÕÕÉä,prophylactic cranial irradiationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎѪ¹Ü,pulmonary vesselÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
NCI-H460ϸ°û,NCI-H460 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
125I·ÅÉäÐÔÁ£×Ó,125I radioactive seedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÇСϸ°û·Î/´úл,non-small cell lung/metabolismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏßÁ£ÌåÈںϵ°°×2,mitofusin 2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æø¹ÜÖ×Áö/Õï¶Ï,Tracheal Neoplasms/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Á×Ö¬õ£¼¡´¼3¼¤Ã¸Í¨µÀ,PI3 K pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ðä×´Çгý,Sleeve resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
99Tcm±ê¼Ç,99Tcm labellingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò©ÎïÄÍÒ©,drug resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈË·ÎÏÙ°©A549ϸ°û,human lung adenocarcinoma A549 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
TÁܰÍÁöÇÖÏ®×ªÒÆÓÕµ¼Òò×Ó1,Tiam 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î×ªÒÆÁö/·ÅÉäÖÎÁÆ,lung metastases/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ó¸ËÖ×¢ÉäÒº,secretio bufonis injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÇàÄêÄÐÐÔ,young menÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢ÈéÍ·½á¹¹,micropapillary patternÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ßƵµçµ¶Êõ,high frequency electrocauteryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©ÅÔ×éÖ¯,Paracancerous tissueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È˷ΰ©Ï¸°ûÖê,human lung cancer cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÁÛ°©,lung squamous carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÑù²¡±ä,tumor-like lesionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î¶¯Âö³ÉÐÎ,Pulmonary arterioplastyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈýάÁ¢ÌåÅàÑø,three-dimensional cultureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÒÊæ,YanshuÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æø¹ÜÇгý,tracheal resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÍÒ©Ïà¹Ø»ùÒò,Drug resistance-related genesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÂÁ¢ÐÔ·ÎÄÚ½á½Ú,Solitary pulmonary noduleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î°©/Õï¶Ï,lung cancer/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·úÍÑÑõÆÏÌÑÌÇF18/Õï¶ÏÓ¦ÓÃ,Fluorodeoxyglucose F18/diagnostic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î¶ñÐÔÖ×Áö,Lung neoplasmÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È˶ËÁ£Ã¸Äæ×ªÂ¼Ã¸»ùÒò,human telomerase reverse transcriptaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ºÚÉ«ËØÁö¿¹Ô»ùÒò,melanoma antigen geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶þÏßÖÎÁÆ,second-line therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏÙÁÛ°©,Adenosquamous carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
É䯵ÏûÈÚÖÎÁÆ,Radiofrequency ablationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Pokemonµ°°×,Pokemon proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Çå½ðµÃÉúƬ,Qing jin de sheng tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Âö¹ÜÁö˨,intravascular cancer embolusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
H460ϸ°û,H460 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
öèÓãÈí¹ÇËØ,shark cartilageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±íƤÉú³¤Òò×Ó/Þ׿¹¼ÁºÍÒÖÖÆ¼Á,Epidermal Growth Factor/antagonists and inhibitorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼××´ÏÙת¼Òò×Ó1,Thyroid transcription factor 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÔ×ªÒÆ°©,cerebral metastatic carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö¿ÉÈÜÐÔ¿¹Ô,tumor soluble antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Å»¯ÁÆÍ¬²½ÖÎÁÆ,Chemo-radiotherapy concomitant therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔÉñ¾ÇÊÁö,Malignant neurilemomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²ÎÂó×¢Éä¼Á,Shenmai injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Àà°©×ÛºÏÕ÷,Carcinoid syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´«Í³Í¿Æ¬,conventional smearÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼Æ»®°ÐÌå»ý,Planning target volumeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¢óÆÚ·ÇСϸ°û·Î°©,stage ¢ó non-small cell lung cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ºó³Ì¼ÓËÙ³¬·Ö¸î·ÅÁÆ,Late course accelerated hyperfractionation radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
KMG΢Çò,KMG microballoonsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏÆ¤Ö×Áö,Epithelial neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍÑÑõ°ûÜÕ/ͶҩºÍ¼ÁÁ¿,deoxycytidine/administration & dosageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿ËÁöÍè,Keliu PillÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÇСϸ°û·Î/ÖÎÁÆ,non-small cell lung/therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö½þÈó×ªÒÆ,Mta1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
LunxmRNA,Lunx mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÅÝϸ°û°©,bronchioloalveolar carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î°©ÈâÁö,Pulmonary CarcinosarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µçÊÓ×ݸô¾µ¼ì²é,Video mediastinoscopyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î°©Ï¸°ûPG,PG cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
caspase9,caspase 9Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÏÙ°©Ï¸°ûÖê,lung adenocarcinoma cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÈâÁö,Pulmonary sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
A-549ϸ°û,A-549 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹®¹Ì»¯ÁÆ,consolidation chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾Ö²¿ÍíÆÚ·ÇСϸ°û·Î°©,local advanced non-small cell lung cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ì춬°±ËáÄÚëÄøÀà,Aspartic endopeptidasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î°©×ªÒÆ,Lung cancer metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ìÔÓÒòËØ,confounding factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³¤´ºÈð±õ/ÖÎÁÆÓ¦ÓÃ,Vinorelbine/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹Èë׸ÊëÄÁò×ªÒÆÃ¸M1,glutathione S-transferase M1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ErbB2µ°°×,ErbB2 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
YB-1µ°°×,YB-1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
VEGF-Cµ°°×,VEGF-C proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹Ö×ÁöÒßÃç,anti-cancer vaccineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò°ÉúÐÍp53,wild type p53Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÂÁöÐÔÊÔÑé,Carcinogenicity testsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|